Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28434217 | 1.00 | CASP3 (0.46) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL30645067 | 0.90 | CASP3 (0.46) | CASP3KMT2APIN1SYK | |
| SCHEMBL1737738 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL31606673 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL29908049 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL15521327 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL7713563 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL7713562 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL22433817 | 0.89 | CASP3 (0.49) | CASP3KMT2APIN1MDM4TP53 | |
| SCHEMBL31512913 | 0.86 | CASP3 (0.47) | CASP3KMT2APIN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | CASP3 1275/4885KMT2A 510/4885PIN1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.